

PRODUCT INFORMATION




Mogroside III E

Item No. 39286

CAS Registry No.: 88901-37-5
Formal Name: (3 β ,9 β ,10 α ,11 α ,24R)-3-(β -D-glucopyranosyloxy)-11,25-dihydroxy-9-methyl-19-norlanost-5-en-24-yl 2-O- β -D-glucopyranosyl- β -D-glucopyranoside

Synonym: MGIIE
MF: C₄₈H₈₂O₁₉
FW: 963.2
Purity: \geq 98%
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years
Item Origin: Plant/*Siraitia grosvenorii* (Swingle)



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mogroside III E is supplied as a solid. A stock solution may be made by dissolving the mogroside III E in the solvent of choice, which should be purged with an inert gas. Mogroside III E is slightly soluble in chloroform and methanol.

Description

Mogroside III E is a cucurbitane glycoside that has been found in *S. grosvenorii* and has anti-inflammatory activity.¹⁻² It inhibits LPS-induced secretion of IL-1 β , IL-6, and TNF- α from, as well as LPS-induced increases in toll-like receptor 4 (TLR4) levels in, RAW 264.7 macrophages when used at a concentration of 50 μ M.¹ Mogroside III E (20 mg/kg) increases in bronchoalveolar lavage fluid (BALF) levels of IL-1 β , IL-6, and TNF- α , and increases in lung tissue myeloperoxidase (MPO) activity in a mouse model of LPS-induced acute lung injury. It decreases lung fibrosis, as well as increases animal survival and reduces lung levels of matrix metalloproteinase-9 (MMP-9), in a mouse model of pulmonary fibrosis induced by the glycopeptide bleomycin (Item No. 13877) when administered at a dose of 20 mg/kg per day.² Formulations containing mogroside III E have been used as sweeteners in food products.

References

1. Tao, L., Cao, F., Xu, G., *et al.* Mogroside III E attenuates LPS-induced acute lung injury in mice partly through regulation of the TLR4/MAPK/NF- κ B axis via AMPK activation. *Phytother. Res.* **31(7)**, 1097-1106 (2017).
2. Tao, L., Yang, J., Cao, F., *et al.* Mogroside III E, a novel anti-fibrotic compound, reduces pulmonary fibrosis through toll-like receptor 4 pathways. *J. Pharmacol. Exp. Ther.* **361(2)**, 268-279 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/06/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM